Evidence map›Paper›PMID 35831294›Full record

ArticleCell death discovery2022

Neddylation tunes peripheral blood mononuclear cells immune response in COVID-19 patients.

Marina Serrano-Maciá, Sofia Lachiondo-Ortega, Paula Iruzubieta, Naroa Goikoetxea-Usandizaga, Alexandre Bosch, Leire Egia-Mendikute, Borja Jiménez-Lasheras, Mikel Azkargorta, Félix Elortza, Diana Martinez-Redondo and 10 more

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Microbiology spectrum · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Role of E3 ubiquitin ligases and deubiquitinating enzymes in SARS-CoV-2 infection.Frontiers in cellular and infection microbiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 1 country.

Marina Serrano-Maciá *Liver Disease Laboratory, CIC bioGUNE-BRTA (Basque Research & Technology Alliance), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.
Sofia Lachiondo-Ortega *Liver Disease Laboratory, CIC bioGUNE-BRTA (Basque Research & Technology Alliance), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.ORCID http://orcid.org/0000-0003-1856-3664
Paula IruzubietaGastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, IDIVAL, Santander, Spain.
Naroa Goikoetxea-UsandizagaLiver Disease Laboratory, CIC bioGUNE-BRTA (Basque Research & Technology Alliance), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.ORCID http://orcid.org/0000-0003-4569-028X
Alexandre BoschCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Leire Egia-MendikuteCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Borja Jiménez-LasherasCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Mikel AzkargortaProteomics Platform, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Carlos IIINetworked Proteomics Platform (ProteoRed-ISCIII), 48160, Derio, Bizkaia, Spain.
Félix ElortzaProteomics Platform, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Carlos IIINetworked Proteomics Platform (ProteoRed-ISCIII), 48160, Derio, Bizkaia, Spain.
Diana Martinez-RedondoHistocell S.L., Bizkaia Science and Technology Park, Derio, Bizkaia, Spain.
Begoña CastroHistocell S.L., Bizkaia Science and Technology Park, Derio, Bizkaia, Spain.
Juan J LozanoBioinformatics Platform, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Catalonia, Spain.
Ruben NogueirasDepartment of Physiology, Research Centre of Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0002-9976-9930
Juan Irure-VenturaServicio Inmunología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Facultad de Medicina, Universidad de Cantabria, Barcelona, Cantabria, Spain.
Javier CrespoGastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, IDIVAL, Santander, Spain.
Asís PalazónCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.ORCID http://orcid.org/0000-0002-7172-7229
María Carmen FariñasServicio Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla-IDIVAL, Facultad de Medicina, Universidad de Cantabria, Barcelona, Cantabria, Spain.
Teresa C DelgadoLiver Disease Laboratory, CIC bioGUNE-BRTA (Basque Research & Technology Alliance), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.ORCID http://orcid.org/0000-0001-9204-581X
Marcos López-HoyosServicio Inmunología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Facultad de Medicina, Universidad de Cantabria, Barcelona, Cantabria, Spain.
Maria L Martínez-ChantarLiver Disease Laboratory, CIC bioGUNE-BRTA (Basque Research & Technology Alliance), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain. mlmartinez@cicbiogune.es.ORCID http://orcid.org/0000-0002-6446-9911
CIC bioGUNE · ESUniversidad de Cantabria · ESEuskadiko Parke Teknologikoa · ESMarqués de Valdecilla University Hospital · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESIkerbasque · ESUniversidade de Santiago de Compostela · ES

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 804236 NEXTGEN-IOFundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) PRDVZ172010SERRMinisterio de Economía, Industria y Competitividad, Gobierno de España (Ministerio de Economía, Industria y Competitividad) PID2019-107956RA-I00Ministerio de Economía, Industria y Competitividad, Gobierno de España (Ministerio de Economía, Industria y Competitividad) PID2020-117116RB-I0Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) COV20/00170
6 · The paper itself

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 has reached 5.5 million deaths worldwide, generating a huge impact globally. This highly contagious viral infection produces a severe acute respiratory syndrome that includes cough, mucus, fever and pneumonia. Likewise, many hospitalized patients develop severe pneumonia associated with acute respiratory distress syndrome (ARDS), along an exacerbated and uncontrolled systemic inflammation that in some cases induces a fatal cytokine storm. Although vaccines clearly have had a beneficial effect, there is still a high percentage of unprotected patients that develop the pathology, due to an ineffective immune response. Therefore, a thorough understanding of the modulatory mechanisms that regulate the response to SARS-CoV-2 is crucial to find effective therapeutic alternatives. Previous studies describe the relevance of Neddylation in the activation of the immune system and its implications in viral infection. In this context, the present study postulates Neddylation, a reversible ubiquitin-like post-translational modification of proteins that control their stability, localization and activity, as a key regulator in the immune response against SARS-CoV-2. For the first time, we describe an increase in global neddylation levels in COVID-19 in the serum of patients, which is particularly associated with the early response to infection. In addition, the results showed that overactivation of neddylation controls activation, proliferation, and response of peripheral blood mononuclear cells (PBMCs) isolated from COVID-19 patients. Inhibition of neddylation, and the subsequent avoidance of activated PBMCs, reduces cytokine production, mainly IL-6 and MCP-1 and induce proteome modulation, being a critical mechanism and a potential approach to immunomodulate COVID-19 patients.

Identifiers

PMID35831294
PMCPMC9277603
OpenAlexW4285091573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.